Development and validation of high-performance thin-layer chromatographic method for the simultaneous determination of rifampicin, isoniazid, and pyrazinamide in a fixed dosage combination tablet

Abstract

Despite being a controllable, preventable, and curable disease,tuberculosis (TB) still remains as a major public health problemin many parts of the world [1, 2]. It is the second leading causeof death from infectious diseases (4% of all deaths), and 88 mil-lion new cases of TB occurred throughout the world during thelast decade [3]. Latent TB infection is present in two billion peo-ple, and 7–8 million new cases are added each year [4, 5].Tuberculosis (TB) is a disease that may have first been identi-fied over 15,000 years ago. Even a century after the discovery ofits cause,